Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells

Dmitri Rozanov, Brock Brown, Cheng-Tien Hung, Eduard Sergienko, Carlton Gasior, Palak Shah, Steve Vasile, Ying Su, Derek Stonich, Patrick Maloney, Greg Roth, Shakeela Dad, Thomas DY Chung
In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
[updated ].
Free Books & Documents
Review

uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells

Dmitri Rozanov et al.
Free Books & Documents

Excerpt

This study proposed to screen for small molecules compounds that selectively sensitize tumor cells to the extrinsic apoptosis pathway activated by Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) without affecting other cell death pathways and normal cells. These compounds represent potentially useful research tools for the elucidation of mechanisms of TRAIL-resistance, and might also serve as prototypic compounds for the development of a new generation of non-toxic anticancer drugs to restore sensitivity to endogenous pathways used by the immune system to eradicate tumors. The probe compound ML100 (CID-3380841) appears to selectively sensitize tumor cells in a TRAIL-dependent manner to the extrinsic apoptosis pathway activated by TRAIL, without effecting normal cells to this apoptosis-inducing cytokine.

PubMed Disclaimer

References

Literature sources for all three probes

    1. Lehnhardt M, Klein-Hitpass L, Kuhnen C, Homann HH, Daigeler A, Steinau HU, Roehrs S, Schnoor L, Steinstraesser L, Mueller O. BMC Cancer. 2005;5:74–89. - PMC - PubMed
    1. Schimmer AD, Thomas PM, Hurren R, Gronda M, Pellecchia M, Pond Gregory R, Konopleva Marina, Gurfinkel Debbie, Mawji Imtiaz A, Brown Ewan, Reed John C. Cancer Res. 2006;66:2367–2375. - PubMed

Bibliography

    1. Jaattela M. Ann Med. 2002;34:480–8. - PubMed
    1. Reed JC. Nat Rev Drug Discov. 2002;1:111–21. - PubMed
    1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. J Clin Invest. 1999;104:155–62. - PMC - PubMed
    1. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Nat Med. 1999;5:157–63. - PubMed
    1. Pittim RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. J Biol Chem. 1996;271:12687–90. - PubMed

LinkOut - more resources